<zgvm class="mmytf"></zgvm>

PA视讯国际

Be the most trusted biotech company

2023-02-01

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Daratumumab Biosimilar HLX15
2023-01-17

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
2023-01-05

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in the US

1
...
5
6
7
8